ROIV vs. VKTX, ASND, LEGN, CERE, CTLT, JAZZ, ITCI, UTHR, ELAN, and CYTK
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Viking Therapeutics (VKTX), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), United Therapeutics (UTHR), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Viking Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Viking Therapeutics received 555 more outperform votes than Roivant Sciences when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 75.00% of users gave Roivant Sciences an outperform vote.
Viking Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Viking Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics presently has a consensus price target of $112.25, indicating a potential upside of 52.43%. Roivant Sciences has a consensus price target of $16.90, indicating a potential upside of 51.84%. Given Roivant Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Viking Therapeutics is more favorable than Roivant Sciences.
Roivant Sciences has a net margin of 3,624.14% compared to Roivant Sciences' net margin of 0.00%. Roivant Sciences' return on equity of -18.41% beat Viking Therapeutics' return on equity.
In the previous week, Viking Therapeutics had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Viking Therapeutics and 2 mentions for Roivant Sciences. Viking Therapeutics' average media sentiment score of 1.43 beat Roivant Sciences' score of 0.83 indicating that Roivant Sciences is being referred to more favorably in the news media.
Summary
Viking Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
